During the past 12 months, Ligand Pharmaceuticals's average EBITDA Per Share Growth Rate was -60.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -35.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -32.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ligand Pharmaceuticals was 206.40% per year. The lowest was -602.40% per year. And the median was 15.90% per year.
Competitive Comparison of Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Ligand Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LGND has been successfully added to your